Aphaia Pharma to Participate in Panel Discussion at SXSW 2025

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, MD, Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at SXSW, taking place March 7-15, 2025, in Austin, Texas.

Details on the panel are as follows:

Panel: Weighing in on Weight Loss Medicine
Date: Monday, March 10, 2025, at 10:00 a.m. CDT
Location: JW Marriot Austin, Salon AB

Learn more about the panel here.

About Aphaia Pharma
Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia’s lead oral candidate, an oral glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. A recently completed Phase 2 trial provided proof-of-concept for its clinical efficacy, demonstrating that the formulation improves glucose tolerance in individuals with prediabetes. The lead candidate is currently being evaluated in a Phase 2 trial for chronic weight management in individuals with obesity. The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple disease patterns.

Aphaia Investor Contact
Günter Jucho
Chief Financial Officer
[email protected]

Media Contact
Madelin Hawtin
LifeSci Communications
[email protected]

You May Also Be Interested In

• DeFi Technologies Announces Shareholder Call to Discuss Q3 2026 Financial Results
• Backblaze Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 3D Systems Announces Agreements to Exchange All Outstanding 5.875% Convertible Senior Secured Notes Due 2030, Eliminating All Secured Debt